Longitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesicles

Platelets

Volumn 27, Issue 1, 2016, Pages 32-42

  Miller, Virginia M ^a,b   Lahr, Brian D ^a   Bailey, Kent R ^a   Heit, John A ^a   Harman, S Mitchell ^c   Jayachandran, Muthuvel ^b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

Estrogen; microparticles; platelet aggregation; platelet derived factor; thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CONJUGATED ESTROGEN; ESTRADIOL; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PLACEBO; PROGESTERONE; PROSTAGLANDIN E1; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; ARTICLE; CELL LYSATE; COMPARATIVE STUDY; DRUG INTERMITTENT THERAPY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY (TOPIC); ORAL MENOPAUSAL HORMONE TREATMENT; PLATELET MICROPARTICLE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TRANSDERMAL MENOPAUSAL HORMONE TREATMENT; TREATMENT OUTCOME; VASCULAR REMODELING; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG EFFECTS; HORMONE SUBSTITUTION; LONGITUDINAL STUDY; MEMBRANE MICROPARTICLE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTE;

ADULT; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LONGITUDINAL STUDIES; MENOPAUSE; MIDDLE AGED; PLATELET AGGREGATION; PROGESTERONE; RISK FACTORS;

EID: 84955384408     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2015.1023273     Document Type: Article

References (45)

1. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985; 7: 89-104
2. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-1109
3. Ernster VL, Bush TL, Huggins GR, Hullka BS, Kelsey JL, Schottenfeld D. Benefits and risks of menopausal estrogen and/or progestin hormone use. Prev Med 1988; 17: 201-223
4. Hodis H, Mack W, Lobo R, Shoupe D, Sevanian A, Mahrer P, Selzer R, Liu C, Liu C, Azen S. Estrogen in the prevention of atherosclerosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939-953
5. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann Intern Med 2014; 161: 249-260
6. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078
7. Lacut K, Oger E, Le Gal G, Blouch M-T, Abgrall J-F, Kerlan V, Scarabin P-V, Mottier D., SARAH Investigators. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003; 90: 124-131
8. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, et al. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation 2007; 115: 840-845
9. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF. Platelet hyperreactivity in women from families with premature atherosclerosis. J Am Med Womens Assoc 2003; 58: 272-277
10. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804
11. Ferroni P, Basili S, Davi G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol 2003; 1: 157-169
12. Calverley DC, Brass E, Hacker MR, Tsao-Wei DD, Espina BM, Pullarkat VA, Hodis HN, Groshen S. Potential role of platelet FcyRIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis 2002; 164: 261-267
13. Raz L, Hunter LW, Jayachandran M, Heit JA, Miller VM. Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets. Physiol Rep 2014; 2: e00275
14. Jayachandran M, Litwiller RD, Owen WG, Miller VM. Circulating microparticles and endogenous estrogen in newly menopausal women. Climacteric 2009; 12: 177-184
15. Raz L, Jayachandran M, Tosakulwong N, Lesnick TG, Wille SM, Murphy MC, Senjem ML, Gunter JL, Vemuri P, Jack CR Jr, et al. Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology 2013; 80: 911-918
16. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3-12
17. Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, et al. Using basic science to design a clinical trial: Baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009; 2: 228-239
18. Jayachandran M, Litwiller RD, Lahr BD, Bailey KR, Owen WG, Mulvagh SL, Heit JA, Hodis HN, Harman SM, Miller VM. Alterations in platelet function and cell-derived microvesicles in recently menopausal women: Relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res 2011; 4: 811-822
19. Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck TR, Mulvagh SL, Araoz PA, Budoff MJ, Harman SM, Miller VM. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol 2008; 295: 931-938
20. McBane RD II, Karnicki K, Tahirkheli N, Miller RS, Owen WG. Platelet characteristics associated with coronary artery disease. J Thromb Haemost 2003; 1: 1296-1303
21. Jimenez TM, Patel SB, Pineda AA, Tefferi A, Owen WG. Factors that influence platelet recovery after transfusion: Resolving donor quality from ABO compatibility. Transfusion 2003; 43: 328-334
22. Splawinska B, Furmaga W, Kuzniar J, Stawiarski M, Pikor I, Szmigiel Z, Splawinski J. Formation of prostacyclin-sensitive platelet aggregates in human whole blood in vitro. Part II. The occurrence of the phenomenon in males suffering from acute myocardial infarction. Scand J Clin Lab Invest 1987; 47: 125-130
23. Wu KK, Hoak JC. Spontaneous platelet aggregation in arterial insufficiency: Mechanisms and implications. Thromb Haemost 1976; 35: 702-711
24. McShine RL, Sibinga S, Brozovic B. Differences between the effects of EDTA and citrate anticoagulants on platelet count and mean platelet volume. Clin Lab Haematol 1990; 12: 277-285
25. Jayachandran M, Miller VM. Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets. Am J Physiol Heart Circ Physiol 2002; 283: H220-H226
26. Jayachandran M, Miller VM, Heit JA, Owen WG. Methodology for isolation, identification and characterization of microvesicles in peripheral blood. J Immunol Methods 2012; 375: 207-214
27. McBane RD II, Karnicki K, Miller RS, Owen WG. The impact of peripheral arterial disease on circulating platelets. Thromb Res 2004; 113: 137-145
28. Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 131-138
29. Farr JN, Khosla S, Miyabara Y, Miller VM, Kearns AE. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab 2013; 98: E249-E257
30. Jayachandran M, Okano H, Chatrath R, Owen WG, McConnell JP, Miller VM. Sex-specific changes in platelet aggregation and secretion with sexual maturity in pigs. J Appl Physiol 2004; 97: 1445-1452
31. Jayachandran M, Mukherjee R, Steinkamp T, LaBreche P, Bracamonte MP, Okano H, Owen WG, Miller VM. Differential effects of 17β-estradiol, conjugated equine estrogen and raloxifene on mRNA expression, aggregation and secretion in platelets. Am J Physiol Heart Circ Physiol 2005; 288: H2355-H2362
32. Jayachandran M, Sanzo A, Owen WG, Miller VM. Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets. Am J Physiol Heart Circ Physiol 2005; 289: H1908-H1916
33. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-2104
34. Wijten P, van Holten T, Woo LL, Bleijerveld OB, Roest M, Heck AJ, Scholten A. High precision platelet releasate definition by quantitative reversed protein profiling-Brief report. Arterioscler Thromb Vasc Biol 2013; 33: 1635-1638
35. Ross R. Platelet-derived growth factor. Lancet 1989; 1: 1179-1182
36. Ross R. Atherosclerosis: The role of endothelial injury, smooth muscle proliferation and platelet factors. Triangle 1976; 15: 4551
37. Xiong J, Miller VM, Hunter LW, Li Y, Jayachandran M. Leukocyte- and platelet-derived microvesicle interactions following in vitro and in vivo activation of toll-like receptor 4 by lipopolysaccharide. PLoS One 2011; 6: e25504
38. McIntyre TM, Prescott SM, Weyrich AS, Zimmerman GA. Cell-cell interactions: Leukocyte-endothelial interactions. Curr Opin Hematol 2003; 10: 150-158
39. Lewandowski KC, Komorowski J, Mikhalidis DP, Bienkiewicz M, Tan BK, O'Callaghan CJ, Lewinski A, Prelevic G, Randeva HS. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006; 91: 3123-3130
40. Herrington DM, Fong J, Sempos CT, Black DM, Schrott HG, Rautaharju P, Bachorik PS, Blumenthal R, Khan S, Wenger NK. Comparison of the heart and estrogen/progestin replacement study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am Heart J 1998; 136: 115-124
41. Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet JM, Tedgui A. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006; 26: 2775-2780
42. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006; 48: 180-186
43. Pirro M, Schillaci G, Paltriccia R, Bagaglia F, Menecali C, Mannarino MR, Capanni M, Velardi A, Mannarino E. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26: 2530-2535
44. Wang JM, Huang YJ, Wang Y, Xu MG, Wang LC, Wang SM, Tao J. Increased circulating CD31+/CD42- microparticles are associated with impaired systemic artery elasticity in healthy subjects. Am J Hypertens 2007; 20: 957-964
45. Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res 2014; 114: 345-353